Pharminent

Merck, Novartis pipeline stunners headline surprisingly good month for CV agents

Merck’s CETP inhibitor anacetrapib and Novartis’ monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category. http://www.mmm-online.com/pipeline/merck-novartis-pipeline-stunners-headline-surprisingly-good-month-for-cv-agents/article/671717/

Filed under: Cardiovascular

Novartis heart drug success opens up new care option

A Novartis anti-inflammatory drug cut cardiovascular risk for heart attack survivors in a pivotal trial, potentially changing ideas about treatment. http://www.cnbc.com/2017/06/22/novartis-heart-drug-success-opens-up-new-care-option.html

Filed under: Cardiovascular

Oral anticoagulants still underutilized in AFib: study

Drugmakers have turned new generation anticoagulants into blockbusters as treatments for strokes and heart attacks, but one area of care where they have made little progress is for treating atrial fibrillation. Cardiology professionals in a new study says that is unfortunate for patients. http://www.fiercepharma.com/pharma/oral-anticoagulants-still-underutilized-afib-study

Filed under: Cardiovascular

Teva launches generic Vytorin tablets in US

Teva Pharmaceutical Industries has launched the generic Vytorin (ezetimibe and simvastatin) tablets in the US. http://drugdelivery.pharmaceutical-business-review.com/news/teva-launches-generic-vytorin-in-us-270417-5798304

Filed under: Cardiovascular

Amgen’s cholesterol drug shows positive effect in cardiovascular outcomes study

Amgen’s cholesterol drug Repatha (evolocumab) has showed positive effect in a 27,564-patient cardiovascular outcomes study. http://clinicaltrials.pharmaceutical-business-review.com/news/amgens-cholesterol-drug-shows-positive-effect-in-cardiovascular-outcomes-study-200317-5766473

Filed under: Cardiovascular, PCSK9

Bayer’s Xarelto Lowers Repeat Blood Clot Risk Better Than Aspirin

ArticleThese late-stage study results were presented in Washington D.C. at the annual American College of Cardiology meeting.Staff Author: Ryan BusheyTopics: Drug Safety http://www.dddmag.com/article/2017/03/bayers-xarelto-lowers-repeat-blood-clot-risk-better-aspirin

Filed under: Cardiovascular

Janssen touts Xarelto’s broader uses, halts CV trial early

The blockbuster blood thinner has proven so effective at preventing heart attack and stroke in certain patients that a global phase 3 study is being stopped more than a year early. http://www.biopharmadive.com/news/janssen-touts-xareltos-broader-uses-halts-cv-trial-early/435852/

Filed under: Cardiovascular

Amgen Keeps Cholesterol Drug Patent vs. Regeneron

http://www.investopedia.com/news/amgen-keeps-patent-vs-regeneron-sanofi-amgn-regn/

Filed under: Cardiovascular, PCSK9

Merck’s Zetia and Vytorin: More Generic Competition in 2017

http://marketrealist.com/2016/12/mercks-zetia-vytorin-expected-witness-increased-generic-competition-2017/

Filed under: Cardiovascular

Reversal agents could unclot the NOAC market

Boehringer bolstered evidence for its antidote Praxbind, but the lack of other reversal agents for new oral anticoagulants has limited overall market growth.  http://www.biopharmadive.com/news/reversal-agents-could-unclot-the-noac-market/430527/

Filed under: Cardiovascular

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for
long-term use, post-heart attack http://www.pmlive.com/pharma_news/nice_backed_expanded_use_of_brilique_in_final_guidance_1175654

Filed under: Cardiovascular

CardioBrief: Eliquis Nipping At Heels of Top-Selling NOAC Xarelto

(MedPage Today) — Overall market for the new oral anticoagulants continues to expand http://www.medpagetoday.com/Cardiology/CardioBrief/60945

Filed under: Cardiovascular

Amgen and Arrowhead to develop gene-therapies for heart disease

(Reuters) – Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and team up with the company to develop gene-silencing therapies for heart disease.
http://www.reuters.com/article/us-amgen-arrowhead-idUSKCN11Z1F3

Filed under: Cardiovascular

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

THOUSAND OAKS, Calif., Sept. 20, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Phase 3 GLAGOV (GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound) trial evaluating the effect of Repatha® (evolocumab) on… http://www.prnewswire.com/news-releases/amgen-announces-positive-top-line-results-from-phase-3-glagov-imaging-study-of-repatha-evolocumab-300330644.html

Filed under: Cardiovascular, PCSK9

ESC: Effient and Brilinta Equal for Post-MI Prevention

(MedPage Today) — PRAGUE-18 trial underpowered but enough to prove no big difference http://www.medpagetoday.com/MeetingCoverage/ESC/59980

Filed under: Cardiovascular

Daiichi Sankyo begins phase 3 ELDERCARE─AF study of anticoagulant edoxaban

Daiichi Sankyo Company, Limited has initiated the ELDERCARE─AF (edoxaban low─dose for elder care AF patients) study aimed at additional dosage and formulation for patients with non─valvular atrial fibrillation http://pharmabiz.com/ArticleDetails.aspx?aid=97067&sid=2

Filed under: Cardiovascular

FDA Delays Approval of Portola’s NOAC Reversal Drug

(MedPage Today) — Agency wants more information http://www.medpagetoday.com/Cardiology/CardioBrief/59741

Filed under: Cardiovascular

AstraZeneca wins UK cost approval for longer use of heart drug

LONDON (Reuters) – Long term use of AstraZeneca’s blood thinner Brilinta has been recommended as a cost-effective option for treating patients after a heart attack, Britain’s healthcare cost watchdog NICE said on Friday.
http://www.reuters.com/article/us-astrazeneca-britain-idUSKCN10M2LY

Filed under: Cardiovascular

When to Avoid Apixaban Dose Reductions in AF: ARISTOTLE Insights

“These data send a strong message to clinicians that apixaban and the other direct oral anticoagulants have to be given at the right dose for the individual patient,” an expert says. Heartwire from Medscape http://www.medscape.com/viewarticle/867075

Filed under: Cardiovascular

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose… http://www.prnewswire.com/news-releases/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor-300296280.html

Filed under: Cardiovascular, PCSK9

Categories